# Psoriasis Drug Market

> Psoriasis Drug Market Research Report: Size, Share, Trend Analysis By Medication Type (Topical Treatments, Systemic Therapies, Biologics), By Route of Administration (Topical, Oral, Injectable), By Disease Severity (Mild to Moderate, Moderate to Severe, Severe) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.32%
- **2024:** $ 31.93 Billion
- **2025:** $ 33.95 Billion
- **2035:** $ 62.65 Billion
- **Key Players:** AbbVie (US), Amgen(US), Johnson & Johnson (US), Novartis (CH), Bristol-Myers Squibb (US), GSK (GB), Eli Lilly (US), Sanofi (FR), UCB (BE)

**Report ID:** MRFR/HC/39241-HCR · **Pages:** 111 · **Author:** Nidhi Mandole · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/psoriasis-drug-market-41292

---

## Market Summary

## **Global Psoriasis Drug Market Overview**

The Psoriasis Drug Market Size was estimated at 28.24 (USD Billion) in 2022.The Psoriasis Drug Industry is expected to grow from 30.03(USD Billion) in 2023 to 52.1 (USD Billion) by 2032. The Psoriasis Drug Market CAGR (growth rate) is expected to be around 6.32% during the forecast period (2024 - 2032).

**Key Psoriasis Drug Market Trends Highlighted**

The rising prevalence of psoriasis, increasing awareness of effective treatments, and advancements in drug development are key drivers of the psoriasis drug market. Continuous improvements in treatment options, including the emergence of novel therapies such as biologics and targeted therapies, have expanded the therapeutic arsenal.Opportunities for growth in the market lie in the development of personalized medicine approaches, focusing on tailoring treatments to individual patient needs. Additionally, there is scope for innovation in combination therapies, leveraging synergies between different mechanisms of action to improve treatment efficacy and reduce side effects.

Collaboration between pharmaceutical companies, academic institutions, and patient advocacy groups is fostering research and development efforts.Recent trends in the psoriasis drug market include a shift towards more targeted and effective therapies, with a focus on reducing systemic exposure and improving patient outcomes. Additionally, there is a growing interest in non-invasive and patient-centric approaches, such as self-injectable biologics and topical formulations, to enhance patient convenience and adherence to treatment regimens. These trends are shaping the future direction of the psoriasis drug market, highlighting the importance of continued investment in research and innovation to address unmet medical needs and improve patient care.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Psoriasis Drug Market Drivers**

**Rising Prevalence of Psoriasis**

Psoriasis, an inflammatory skin disease, has become increasingly common among millions of people worldwide. Although the frequency of this disease has grown in recent years, this trend is expected to continue in future years. Due to several reasons, including a greater understanding of the disease, better diagnosis and treatment options and the increased prevalence of people with chronic conditions, the prevalence of psoriasis is on the rise. A growing number of patients being diagnosed with psoriasis is one of the key factors boosting the development of the psoriasis drugs market.

**Growing Demand for Biologic Drugs**

Biologic drugs are medications applied for the treatment of psoriasis. It has been proved that they work by targeting specific proteins in the immune system involved in the development of psoriasis. Recently, biologic drugs have gained wide popularity as they are highly efficient for treating the disease. The growth of the psoriasis drug market is mainly driven by the rising interest in biologic drugs. That is to say, as more patients are inclined to use such drugs, the demand for them increases.

**Increasing Research and Development**

There is a significant amount of research and development (R) being conducted in the field of psoriasis. This R is focused on developing new and more effective treatments for psoriasis. The increasing R in this field is a major driver of the growth of the psoriasis drug market. As new and more effective treatments are developed, the demand for these treatments will increase.

**Psoriasis Drug Market Segment Insights**

**Psoriasis Drug Market Medication Type Insights**

The psoriasis drugs market, according to the medication type, is classified into topical treatment, systemic therapies and biologics. Topical treatment, which typically involves the use of ointments, creams, and lotions applied directly to the skin, is considered the major contributor, generating more than 45% of the revenue as of 2023. They are known for treating the area, relatively safe and well-tolerated. Nonetheless, efficacy may be questionable for severe psoriasis. Systemic therapies usually consist of pills or injections that treat moderate or severe psoriasis.They work by suppressing the overactive immune system and reducing inflammation.

In recent years, systemic therapies have demonstrated significant growth and are expected to continue due to the gradual and constant development of new and more efficient methods. Biologics are a relatively new therapy for treating psoriasis. These drugs are derived from living sources and are generally much more efficient in treatment. Biologics act on specific immune system proteins.

The biologics type of the market is forecasted to be the fastest-growing, with an increasing number of available, newer drugs.The psoriasis drugs market is an extremely competitive one, with a number of major pharmaceutical giants investing heavily and competing in the acquisition and development of better drugs. The largest major players are AbbVie, Novartis, Eli Lilly and Co., and Johnson Johnson. The dropIndexPsoriasis market is expected to be extremely competitive in the coming years. AbbVie, Novartis, J, and Eli Lily are some of the major players in the market.

The companies are continuously investing in acquiring other, smaller companies or developing new drugs on their own.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Psoriasis Drug Market Route of Administration Insights**

The Psoriasis Drug Market is segmented by Route of Administration into Topical, Oral and Injectable. In 2023, a topical segment of the market dominated the market and is expected to dominate in the forecast period as well. The topical segment holds an approximately 55% value share of the market. The usage of topical formulations has the least side effects, like oral administration, but it is easy to use because of the availability of creams, ointments, and gel formulations.

The Oral segment is expected to be the fastest-growing segment in the forecast period.The usage of oral therapies for moderate-to-severe psoriasis is growing to systemically treat the condition and offer better control of symptoms and long-term benefits. The Injectable segment is expected to grow at a medium pace, mainly because the approvals of new injectable biologics for the treatment of psoriasis are increasing.

**Psoriasis Drug Market Disease Severity Insights**

The Psoriasis Drug Market is segmented into mild to moderate, moderate to severe, and severe disease severity. The severe segment held the largest market share in 2023, accounting for over 40% of the Psoriasis Drug Market revenue. The moderate to severe segment is expected to grow at the highest CAGR during the forecast period due to the increasing prevalence of moderate to severe psoriasis and the availability of new and effective treatments. The mild to moderate segment is expected to grow at a steady pace due to the increasing awareness of psoriasis and the availability of over-the-counter treatments.

**Psoriasis Drug Market Regional Insights**

The Psoriasis Drug Market is segmented into North America, Europe, APAC, South America and MEA. North America dominates the market with a revenue of USD 12.4 billion in 2023 and is expected to reach USD 20.7 billion by 2032, growing at a CAGR of 6.5%. Europe is the second-largest market, with a revenue of USD 9.8 billion in 2023 and is expected to reach USD 16.3 billion by 2032, growing at a CAGR of 6.7%.

APAC is the fastest-growing region, with a revenue of USD 6.2 billion in 2023 and is expected to reach USD 11.4 billion by 2032, growing at a CAGR of 7.5%.South America and MEA are expected to grow at a CAGR of 6.0% and 5.8%, respectively, over the forecast period. The growth in the regional markets is attributed to the increasing prevalence of psoriasis, rising disposable income, and growing awareness of advanced treatment options.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Psoriasis Drug Market Key Players And Competitive Insights**

The Psoriasis Drug Market competitive environment is one of the most flexible and dynamic, having numerous players, both well-established and emerging, competing for the share of the market. Hence, current prominent companies in the Psoriasis Drug Market include AbbVie, Novartis, Eli Lilly and Company, Janssen Pharmaceuticals and Celgene Corporation, among others. The market for Psoriasis Drugs is becoming increasingly competitive as leading companies focus on the development of innovative and effective drugs to meet the growing needs of the patient population.

Leading companies also spend an ever-growing amount of time and resources on research and development to ensure access to a wider selection of medication and collaborate in various ways to enhance the industry, as it enables companies to pool resources to address the existing unmet needs in the health sector. Moreover, mergers and acquisitions are an excellent way for pharmaceutical companies to increase their presence in certain segments or geographic locations or strengthen their positions in the market, specifically, in this case, Psoriasis Drug Market.AbbVie is one of the leaders in the Psoriasis Drug Market.

The company is one of the globally known biopharmaceutical companies with a focus on developing potentially promising and viable solutions to treat different diseases, including psoriasis. Humira is known to be a highly effective medication to treat Psoriasis, and it has become one of the most commonly used drugs for moderate to severe psoriasis. In addition, Humira has a positive effect on joints, which is particularly significant as psoriatic arthritis remains one of the most challenging forms of the disease to treat.

AbbVie has also made commendable progress in immunology and successfully brought new solutions, recently launching Skyrizi, which is a next-generation biologic medication for patients with psoriasis with high efficacy. As far as Janssen Pharmaceuticals, a subsidiary of Johnson Johnson, is concerned, the company has also made a great contribution to the development of the Psoriasis Drug Market. Being active since the mid-2000s and currently offers a range of psoriasis medications such as Stelara, an average Psoriasis medication, and Tremfya, one of the clearly visible next-generation medications with even higher efficacy as they are more target-oriented in comparison to their predecessors.

In addition, Janssen Pharmaceuticals also made great progress in researching the issue of psoriasis, discovering promising molecules with high efficacy and good safety profiles of several such molecules. Further, Janssen Pharmaceuticals has excellent access to the commercial market, and its patient- and operator-centered approach has ensured a positive position in the Psoriasis Drug Market.

**Key Companies in the Psoriasis Drug Market Include**

### Psoriasis Drug Market Industry Developments

- **Q2 2024: MoonLake Immunotherapeutics Announces Positive Results from Phase 3 Trial of Sonelokimab in Psoriasis** MoonLake Immunotherapeutics reported positive top-line results from its Phase 3 trial of Sonelokimab, a novel biologic for moderate-to-severe plaque psoriasis, paving the way for regulatory submission.
- **Q2 2024: AnaptysBio Announces FDA Acceptance of Imsidolimab Biologics License Application for Generalized Pustular Psoriasis** AnaptysBio announced that the FDA has accepted its Biologics License Application for Imsidolimab, a monoclonal antibody targeting IL-36, for the treatment of generalized pustular psoriasis.
- **Q2 2024: Takeda and Nimbus Announce Strategic Partnership to Develop TAK-279 for Psoriasis** Takeda and Nimbus Lakshmi entered a strategic partnership to co-develop TAK-279, a TYK2 inhibitor, for the treatment of moderate-to-severe psoriasis.
- **Q3 2024: UCB Receives FDA Approval for BIMZELX (bimekizumab) for Moderate to Severe Plaque Psoriasis** UCB announced that the FDA has approved BIMZELX (bimekizumab), a dual IL-17A and IL-17F inhibitor, for the treatment of adults with moderate to severe plaque psoriasis.
- **Q3 2024: Dermavant Secures $200 Million Series C Funding to Advance VTAMA Cream for Psoriasis** Dermavant Sciences raised $200 million in Series C funding to support the commercialization and further development of VTAMA (tapinarof) cream for plaque psoriasis.
- **Q4 2024: MoonLake Immunotherapeutics Submits Marketing Authorization Application for Sonelokimab to EMA** MoonLake Immunotherapeutics submitted a Marketing Authorization Application to the European Medicines Agency for Sonelokimab, targeting moderate-to-severe plaque psoriasis.
- **Q4 2024: AbbVie Announces FDA Approval of SKYRIZI for Expanded Psoriasis Indication** AbbVie received FDA approval for an expanded indication of SKYRIZI (risankizumab-rzaa) to include treatment of adults with erythrodermic psoriasis.
- **Q1 2025: Novartis Launches Cosentyx Autoinjector Device for Psoriasis Patients in the US** Novartis launched a new autoinjector device for Cosentyx, designed to improve ease of use for patients with moderate-to-severe plaque psoriasis in the United States.
- **Q1 2025: Amgen Announces Opening of New Biologics Manufacturing Facility to Support Psoriasis Drug Production** Amgen opened a new biologics manufacturing facility in North Carolina to increase production capacity for its psoriasis drug portfolio.
- **Q2 2025: Eli Lilly Receives FDA Approval for Mirikizumab for Moderate to Severe Plaque Psoriasis** Eli Lilly announced FDA approval of Mirikizumab, an IL-23p19 antagonist, for the treatment of adults with moderate to severe plaque psoriasis.
- **Q2 2025: Bristol Myers Squibb Announces European Commission Approval of Sotyktu for Psoriasis** Bristol Myers Squibb received European Commission approval for Sotyktu (deucravacitinib), a TYK2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis.
- **Q3 2025: Janssen Announces FDA Approval of Tremfya for Pediatric Plaque Psoriasis** Janssen, a Johnson & Johnson company, announced FDA approval of Tremfya (guselkumab) for the treatment of pediatric patients with moderate-to-severe plaque psoriasis.

**Psoriasis Drug Market Segmentation Insights**

**Psoriasis Drug Market Medication Type Outlook**

**Psoriasis Drug Market Route of Administration Outlook**

**Psoriasis Drug Market Disease Severity Outlook**

**Psoriasis Drug Market Regional Outlook**

## Market Drivers

### Rising Awareness and Education

Increased awareness and education regarding psoriasis are driving the Psoriasis Drug Market. Campaigns aimed at educating both healthcare professionals and patients about the condition have led to improved diagnosis and treatment rates. As individuals become more informed about available therapies, they are more likely to seek treatment, thereby expanding the market. Furthermore, healthcare providers are increasingly recognizing the importance of early intervention, which can lead to better management of the disease. This heightened awareness is reflected in the growing number of support groups and online resources dedicated to psoriasis, fostering a community that encourages individuals to pursue effective treatment options. Consequently, the Psoriasis Drug Market is poised for growth as more patients engage with healthcare systems.

### Advancements in Drug Development

Technological advancements in drug development are significantly influencing the Psoriasis Drug Market. The emergence of novel therapeutic agents, particularly biologics and small molecules, has transformed treatment paradigms. For instance, the introduction of targeted therapies has shown promising results in clinical trials, leading to higher efficacy rates and improved patient outcomes. The market is projected to witness substantial growth, with estimates suggesting a compound annual growth rate (CAGR) of over 10% in the coming years. These advancements not only enhance treatment options but also attract investment from pharmaceutical companies eager to capitalize on innovative solutions. As a result, the Psoriasis Drug Market is likely to experience a surge in new product launches, catering to diverse patient needs and preferences.

### Increasing Prevalence of Psoriasis

The rising incidence of psoriasis is a pivotal driver for the Psoriasis Drug Market. Recent estimates indicate that psoriasis affects approximately 2-3% of the population in various regions, translating to millions of individuals seeking effective treatment options. This growing patient population necessitates the development and availability of innovative therapies, thereby propelling market growth. As awareness of the condition increases, more individuals are likely to seek medical advice and treatment, further expanding the market. The increasing prevalence is also linked to lifestyle factors, such as obesity and stress, which may exacerbate the condition. Consequently, pharmaceutical companies are motivated to invest in research and development to address this unmet medical need, thereby enhancing their market presence in the Psoriasis Drug Market.

### Regulatory Support for New Treatments

Regulatory bodies are playing a crucial role in shaping the Psoriasis Drug Market by facilitating the approval of new treatments. Initiatives aimed at expediting the review process for innovative therapies have led to a more dynamic market environment. For instance, the introduction of fast-track designations for promising drugs has encouraged pharmaceutical companies to invest in research and development. This regulatory support not only accelerates the availability of new treatments but also instills confidence in investors and stakeholders. As a result, the market is likely to see an influx of novel therapies that address various aspects of psoriasis, catering to the diverse needs of patients. This trend underscores the importance of regulatory frameworks in fostering innovation within the Psoriasis Drug Market.

### Growing Demand for Combination Therapies

The increasing demand for combination therapies is emerging as a significant driver in the Psoriasis Drug Market. Patients often experience varying degrees of severity and may not respond adequately to monotherapy. As a result, healthcare providers are increasingly adopting combination approaches that integrate multiple treatment modalities to enhance efficacy and minimize side effects. This trend is supported by clinical evidence suggesting that combination therapies can lead to improved patient outcomes. The market is witnessing a shift towards personalized treatment regimens, with estimates indicating that combination therapies could account for a substantial share of the market in the coming years. This evolving landscape highlights the need for pharmaceutical companies to innovate and develop synergistic treatment options within the Psoriasis Drug Market.

## Future Outlook

The Psoriasis Drug Market is projected to grow at a 6.32% CAGR from 2025 to 2035, driven by advancements in biologics, increasing prevalence, and rising healthcare expenditure.

**New opportunities:**

- Development of personalized biologic therapies targeting specific patient profiles. Expansion of telehealth services for remote patient monitoring and consultations. Investment in digital health platforms for enhanced patient engagement and adherence.

By 2035, the Psoriasis Drug Market is expected to achieve substantial growth, reflecting evolving treatment paradigms.

## Segment Insights

### By Type: Topical Treatments (Largest) vs. Biologics (Fastest-Growing)

The psoriasis drug market exhibits a varied distribution among its primary segments: topical treatments, systemic therapies, and biologics. Topical treatments maintain a strong foothold due to their accessibility and longstanding use, appealing to both patients and healthcare providers. In contrast, biologics have emerged as a pivotal player, satisfying the needs of patients with moderate to severe psoriasis who require more advanced therapeutic options. Systemic therapies occupy the middle ground, showcasing steady usage among patients.

Topical Treatments (Dominant) vs. Biologics (Emerging)

Topical treatments account for a significant proportion of the psoriasis drug market, primarily due to their effectiveness and ease of use. These treatments, including steroids and vitamin D analogs, are often the first line of therapy for patients with mild to moderate psoriasis. Biologics, on the other hand, represent the fastest-growing category as they offer targeted therapies with improved efficacy for those with more severe forms of the disease. Their emergence is attributed to advancements in biotechnology and increased awareness among dermatologists and patients about the benefits of these innovative treatments, leading to a shift toward more specialized care.

### By Route of Administration: Topical (Largest) vs. Injectable (Fastest-Growing)

The Route of Administration segment in the Psoriasis Drug Market reveals a competitive landscape dominated by Topical treatments, which provide a significant share of the market due to their targeted delivery and ease of use. Oral administration follows as a steady player, appealing to a wide range of patients, while Injectables are quickly gaining traction as an effective long-term treatment option. Each segment plays a vital role in treatment regimens, catering to diverse patient needs and preferences. Looking at growth trends, Injectable treatments in the Psoriasis Drug Market are experiencing the fastest growth, driven by advancements in biologic therapies that offer enhanced efficacy and safety profiles. As patient awareness of treatment options increases, the demand for more effective injectable solutions continues to rise. The Oral segment benefits from its versatility, but it is the Injectables that are positioning themselves as the future of psoriasis management, paving the way for innovative therapies and more personalized approaches to care.

Topical (Dominant) vs. Injectable (Emerging)

Topical treatments have long been the cornerstone of psoriasis management, representing a dominant force in this segment. Their non-invasive nature, coupled with direct application to affected areas, provides effective and immediate relief for patients. Various formulations, including creams, lotions, and ointments, offer tailored therapeutic options to suit different patient needs. This dominance is supported by continuous research and development, resulting in improved product efficacy and patient adherence. On the other hand, the Injectable segment is emerging rapidly, primarily due to the introduction of novel biologics that target specific pathways involved in psoriasis. These treatments are particularly appealing to patients with moderate to severe cases where traditional therapies have failed. The convenience of fewer dosing schedules compared to oral alternatives enhances patient compliance and engagement, marking Injectables as a significant player in the evolving treatment landscape.

### By Disease Severity: Moderate to Severe (Largest) vs. Mild to Moderate (Fastest-Growing)

The Psoriasis Drug Market is primarily segmented by disease severity, where the Moderate to Severe category holds the largest market share. This segment's prevalence among patients significantly influences market dynamics, driven by the increasing recognition of the debilitating effects of psoriasis. In contrast, the Mild to Moderate segment is emerging rapidly, gaining traction due to a growing emphasis on early treatment interventions and the acknowledgment that even mild cases necessitate effective management. This leads to broader market engagement in this category, enhancing its competitive landscape.

Mild to Moderate (Emerging) vs. Moderate to Severe (Dominant)

In the Psoriasis Drug Market, the Mild to Moderate segment is gaining momentum as an emerging focal point due to shifting perceptions among healthcare providers and patients. While traditionally less prioritized, there is a growing realization that this segment represents a substantial population segment that requires effective therapies. The Moderate to Severe segment, on the other hand, continues to dominate as it engages a larger patient base with more complex treatment needs. Both segments are essential, with Mild to Moderate potentially revolutionizing clinical approaches by advocating early intervention strategies and expanding treatment accessibility, while Moderate to Severe drives innovation and high-value drug development.

## Regional Market Share Analysis

The Psoriasis Drug Market is segmented into North America, Europe, APAC, South America and MEA. North America dominates the market with a revenue of USD 12.4 billion in 2023 and is expected to reach USD 20.7 billion by 2032, growing at a CAGR of 6.5%. Europe is the second-largest market, with a revenue of USD 9.8 billion in 2023 and is expected to reach USD 16.3 billion by 2032, growing at a CAGR of 6.7%.

APAC is the fastest-growing region, with a revenue of USD 6.2 billion in 2023 and is expected to reach USD 11.4 billion by 2032, growing at a CAGR of 7.5%.South America and MEA are expected to grow at a CAGR of 6.0% and 5.8%, respectively, over the forecast period. The growth in the regional markets is attributed to the increasing prevalence of psoriasis, rising disposable income, and growing awareness of advanced treatment options.

## Competitive Benchmarking

The Psoriasis Drug Market competitive environment is one of the most flexible and dynamic, having numerous players, both well-established and emerging, competing for the share of the market. Hence, current prominent companies in the Psoriasis Drug Market include AbbVie, Novartis, Eli Lilly and Company, Janssen Pharmaceuticals and Celgene Corporation, among others. The market for Psoriasis Drugs is becoming increasingly competitive as leading companies focus on the development of innovative and effective drugs to meet the growing needs of the patient population. Leading companies also spend an ever-growing amount of time and resources on research and development to ensure access to a wider selection of medication and collaborate in various ways to enhance the industry, as it enables companies to pool resources to address the existing unmet needs in the health sector. Moreover, mergers and acquisitions are an excellent way for pharmaceutical companies to increase their presence in certain segments or geographic locations or strengthen their positions in the market, specifically, in this case, Psoriasis Drug Market.AbbVie is one of the leaders in the Psoriasis Drug Market. The company is one of the globally known biopharmaceutical companies with a focus on developing potentially promising and viable solutions to treat different diseases, including psoriasis. Humira is known to be a highly effective medication to treat Psoriasis, and it has become one of the most commonly used drugs for moderate to severe psoriasis. In addition, Humira has a positive effect on joints, which is particularly significant as psoriatic arthritis remains one of the most challenging forms of the disease to treat. AbbVie has also made commendable progress in immunology and successfully brought new solutions, recently launching Skyrizi, which is a next-generation biologic medication for patients with psoriasis with high efficacy. As far as Janssen Pharmaceuticals, a subsidiary of Johnson Johnson, is concerned, the company has also made a great contribution to the development of the Psoriasis Drug Market. Being active since the mid-2000s and currently offers a range of psoriasis medications such as Stelara, an average Psoriasis medication, and Tremfya, one of the clearly visible next-generation medications with even higher efficacy as they are more target-oriented in comparison to their predecessors. In addition, Janssen Pharmaceuticals also made great progress in researching the issue of psoriasis, discovering promising molecules with high efficacy and good safety profiles of several such molecules. Further, Janssen Pharmaceuticals has excellent access to the commercial market, and its patient- and operator-centered approach has ensured a positive position in the Psoriasis Drug Market.

## Recent News & Developments

- **Q2 2024: MoonLake Immunotherapeutics Announces Positive Results from Phase 3 Trial of Sonelokimab in Psoriasis** MoonLake Immunotherapeutics reported positive top-line results from its Phase 3 trial of Sonelokimab, a novel biologic for moderate-to-severe plaque psoriasis, paving the way for regulatory submission.
- **Q2 2024: AnaptysBio Announces FDA Acceptance of Imsidolimab Biologics License Application for Generalized Pustular Psoriasis** AnaptysBio announced that the FDA has accepted its Biologics License Application for Imsidolimab, a monoclonal antibody targeting IL-36, for the treatment of generalized pustular psoriasis.
- **Q2 2024: Takeda and Nimbus Announce Strategic Partnership to Develop TAK-279 for Psoriasis** Takeda and Nimbus Lakshmi entered a strategic partnership to co-develop TAK-279, a TYK2 inhibitor, for the treatment of moderate-to-severe psoriasis.
- **Q3 2024: UCB Receives FDA Approval for BIMZELX (bimekizumab) for Moderate to Severe Plaque Psoriasis** UCB announced that the FDA has approved BIMZELX (bimekizumab), a dual IL-17A and IL-17F inhibitor, for the treatment of adults with moderate to severe plaque psoriasis.
- **Q3 2024: Dermavant Secures $200 Million Series C Funding to Advance VTAMA Cream for Psoriasis** Dermavant Sciences raised $200 million in Series C funding to support the commercialization and further development of VTAMA (tapinarof) cream for plaque psoriasis.
- **Q4 2024: MoonLake Immunotherapeutics Submits Marketing Authorization Application for Sonelokimab to EMA** MoonLake Immunotherapeutics submitted a Marketing Authorization Application to the European Medicines Agency for Sonelokimab, targeting moderate-to-severe plaque psoriasis.
- **Q4 2024: AbbVie Announces FDA Approval of SKYRIZI for Expanded Psoriasis Indication** AbbVie received FDA approval for an expanded indication of SKYRIZI (risankizumab-rzaa) to include treatment of adults with erythrodermic psoriasis.
- **Q1 2025: Novartis Launches Cosentyx Autoinjector Device for Psoriasis Patients in the US** Novartis launched a new autoinjector device for Cosentyx, designed to improve ease of use for patients with moderate-to-severe plaque psoriasis in the United States.
- **Q1 2025: Amgen Announces Opening of New Biologics Manufacturing Facility to Support Psoriasis Drug Market Production** Amgen opened a new biologics manufacturing facility in North Carolina to increase production capacity for its psoriasis drug portfolio.
- **Q2 2025: Eli Lilly Receives FDA Approval for Mirikizumab for Moderate to Severe Plaque Psoriasis** Eli Lilly announced FDA approval of Mirikizumab, an IL-23p19 antagonist, for the treatment of adults with moderate to severe plaque psoriasis.
- **Q2 2025: Bristol Myers Squibb Announces European Commission Approval of Sotyktu for Psoriasis** Bristol Myers Squibb received European Commission approval for Sotyktu (deucravacitinib), a TYK2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis.
- **Q3 2025: Janssen Announces FDA Approval of Tremfya for Pediatric Plaque Psoriasis** Janssen, a Johnson & Johnson company, announced FDA approval of Tremfya (guselkumab) for the treatment of pediatric patients with moderate-to-severe plaque psoriasis.

## Report Scope

| MARKET SIZE 2024 | 31.93(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 33.95(USD Billion) |
| MARKET SIZE 2035 | 62.65(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.32% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | AbbVie (US), Amgen (US), Johnson & Johnson (US), Novartis (CH), Bristol-Myers Squibb (US), GSK (GB), Eli Lilly (US), Sanofi (FR), UCB (BE) |
| Segments Covered | Medication Type, Route of Administration, Disease Severity, Regional |
| Key Market Opportunities | Emergence of biologics and targeted therapies enhances treatment options in the Psoriasis Drug Market. |
| Key Market Dynamics | Rising demand for biologics drives innovation and competition in the psoriasis drug market, influencing treatment options. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Psoriasis Drug Market as of 2024?**
A: The Psoriasis Drug Market was valued at 31.93 USD Billion in 2024.

**Q: What is the projected market size for the Psoriasis Drug Market in 2035?**
A: The market is projected to reach 62.65 USD Billion by 2035.

**Q: What is the expected CAGR for the Psoriasis Drug Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Psoriasis Drug Market during 2025 - 2035 is 6.32%.

**Q: Which companies are the key players in the Psoriasis Drug Market?**
A: Key players include AbbVie, Amgen, Johnson & Johnson, Novartis, Bristol-Myers Squibb, GSK, Eli Lilly, Sanofi, and UCB.

**Q: What are the main segments of the Psoriasis Drug Market?**
A: The main segments include Topical Treatments, Systemic Therapies, and Biologics.

**Q: How much did the Topical Treatments segment generate in 2024?**
A: The Topical Treatments segment generated 8.0 USD Billion in 2024 and is projected to reach 15.0 USD Billion.

**Q: What is the market size for Systemic Therapies in 2024?**
A: The Systemic Therapies segment was valued at 10.0 USD Billion in 2024 and is expected to grow to 20.0 USD Billion.

**Q: What is the projected growth for the Biologics segment by 2035?**
A: The Biologics segment is projected to grow from 13.93 USD Billion in 2024 to 27.65 USD Billion by 2035.

**Q: How does disease severity impact the Psoriasis Drug Market?**
A: The market segments by disease severity include Mild to Moderate, Moderate to Severe, and Severe, with valuations ranging from 9.93 to 24.0 USD Billion.

**Q: What routes of administration are prevalent in the Psoriasis Drug Market?**
A: The prevalent routes of administration include Topical, Oral, and Injectable, with respective valuations of 8.0, 10.0, and 13.93 USD Billion in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/psoriasis-drug-market-41292*